| Confronting the type 2 diabetes epidemic: the emerging role of incretin-based therapies. | |
| | |
MedLine Citation:
|
PMID: 20609666 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
This report highlights a roundtable discussion that occurred during the annual meeting of the International Diabetes Federation (IDF) in November 2009, in Montreal, Quebec, Canada. Participants included Bernard Zinman, MD, Michael A. Nauck, MD, PhD, Jorge Plutzky, MD, and Allison B. Goldfine, MD. The roundtable was chaired by Vivian A. Fonseca, MD. Among the topics discussed were the burden of type 2 diabetes mellitus and the importance of "appropriate therapy," which includes not only managing glycemia but also the management of concomitant risk factors such as hypertension and dyslipidemia. The discussants also identified issues that remain to be resolved, such as determining the nature of first-line therapy (e.g., should initial dual-agent therapy be encouraged?) and agreeing upon the most appropriate agent to be combined with metformin, which is the current standard of care. Among the new treatments discussed for type 2 diabetes were the analogues of the incretin hormones glucagonlike peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), namely, the GLP-1 receptor agonists-as well as the inhibitors of dipeptidyl peptidase-4 (DPP-4), the enzyme that regulates the bioactivity of the endogenous incretin hormones. These agents have some interesting advantages; not only do they effectively lower glucose, but they also have demonstrated beneficial metabolic and cardiovascular effects. Particularly with respect to the GIP and GLP-1, weight loss, blood pressure reductions, and beta-cell function improvements have been observed in clinical trials. What remains to be determined, by means of additional clinical experience and perhaps additional head-to-head trials, are the long-term benefits of GLP-1 receptor agonists and DPP-4 inhibitors and the sorts of roles these 2 classes of agents may play in the type 2 diabetes therapeutic continuum. |
| | |
Authors:
|
Vivian A Fonseca; Bernard Zinman; Michael A Nauck; Allison B Goldfine; Jorge Plutzky |
Related Documents
:
|
20675986 - The many faces of type 2 diabetes. 1486906 - Mechanisms of diuretic effects on carbohydrate tolerance, insulin sensitivity and lipid... 19690556 - Therapy: intensive glucose control in the icu: is sugar nice? 12099966 - Changes in treatment after the start of oral hypoglycaemic therapy in type 2 diabetes: ... 16567516 - Insulin signaling in human visceral and subcutaneous adipose tissue in vivo. 19835616 - Stem cell therapy for type 1 diabetes mellitus: a review of recent clinical trials. |
Publication Detail:
|
Type: Interactive Tutorial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: The American journal of medicine Volume: 123 ISSN: 1555-7162 ISO Abbreviation: Am. J. Med. Publication Date: 2010 Jul |
Date Detail:
|
Created Date: 2010-07-08 Completed Date: 2010-07-29 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0267200 Medline TA: Am J Med Country: United States |
Other Details:
|
Languages: eng Pagination: S2-S10 Citation Subset: AIM; IM |
Affiliation:
|
Tulane University Health Sciences Center, New Orleans, Louisiana, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Diabetes Mellitus, Type 2
/
drug therapy*,
epidemiology Disease Outbreaks Humans Hypoglycemic Agents / therapeutic use* Incretins / adverse effects, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Hypoglycemic Agents; 0/Incretins |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Reply.
Next Document: The reply.